The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JAVEMACS chart review study of avelumab maintenance in patients with advanced urothelial carcinoma (aUC) in Japan: Analyses of subgroups defined by second-line (2L) treatment.
 
Takashi Kobayashi
Honoraria - Astellas Pharma; Bayer; Janssen; MSD
Consulting or Advisory Role - Astellas Pharma; Janssen
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma
 
Hiroshi Kitamura
Honoraria - Astellas Pharma; AstraZeneca/Daiichi Sankyo; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Merck/Pfizer; MSD; Nippon Kayaku; Nippon Shinyaku; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; MSD; Pfizer; Takeda
Research Funding - Bristol-Myers Squibb Japan (Inst); Janssen (Inst)
 
Go Kimura
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Merck; MSD; Nihonkayaku; Ono Yakuhin; Sanofi; Takeda
 
Masaomi Ikeda
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; EP biopharma; Haihe Pharmaceutical; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Norihiko Kawamura
No Relationships to Disclose
 
Atsuko Fujihara
No Relationships to Disclose
 
Takashige Abe
No Relationships to Disclose
 
Fumitaka Shimizu
No Relationships to Disclose
 
Kiyohide Fujimoto
No Relationships to Disclose
 
Tohru Nakagawa
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Ono Pharmaceutical
Research Funding - Terumo Life Science Foundation (Inst)
 
Shingo Hatakeyama
Speakers' Bureau - AstraZeneca; Janssen; Merck KGaA
Research Funding - Nipro Corporation (Inst); Oyokyo Kidney Research Institute Hirosaki Hospital (Inst)
Other Relationship - Kaneka Medix Corporation
 
Kaoru Murakami
No Relationships to Disclose
 
Kiyoaki Nishihara
No Relationships to Disclose
 
Daiki Ikarashi
No Relationships to Disclose
 
Naoya Masumori
Honoraria - Ono Yakuhin; Takeda Science Foundation
Research Funding - MSD Oncology (Inst); Ono Yakuhin (Inst)
 
Anzu Kambe
Employment - Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany
 
Michihiro Shono
Employment - Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany
 
Suguru Shirotake
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ferring; Janssen; Merck; MSD; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; Merck; MSD; Nippon Kayaku; Sanofi; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); Merck (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)